EP1.05-02 Endobronchial Ultrasound and Transbronchial Needle Aspiration EBUS-TBNA: In a University Hospital in Latin America

Abstract

survival was 3.73 months (95% CI 2.8-4.2). Factors associated with increased survival included treatment as first-line (p <0.001), type of response (p <0.001) and PD-L1 status (p ¼ 0.0039). Compared with the historical cohort, immunotherapy proved to be superior in terms of OS (p¼ 0.05) but not PFS (p¼ 0.2). Conclusion: Patients who receive immune checkpoint inhibitors as part of their treatment for NSCLC have better OS compared with matched patients treated with standard chemotherapy, regardless of treatment line.